Zostavax
Sponsors
Merck Sharp & Dohme LLC, National Institute of Allergy and Infectious Diseases (NIAID), University of Zurich, McMaster University, Emory University
Conditions
FibrosisHIV InfectionsHerpes ZosterImmune System DiseasesImmunization; InfectionPrevention of : Herpes-ZosterShinglesSystemic Lupus Erythematosus
Phase 1
Prevention of Varicella Zoster Virus (VZV)-Reactivation in HIV-positive Individuals Enrolled in a Prospective Immunogenicity and Safety Trial of VZV Vaccine: PROVE-IT-Study
WithdrawnNCT01213810
Start: 2010-12-31End: 2012-06-30Updated: 2013-03-01
Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds
CompletedNCT02114333
Start: 2014-05-31End: 2020-05-31Updated: 2020-07-08
Safety Study of NBP608 in Healthy Adult Volunteers
CompletedNCT03121638
Start: 2012-11-30End: 2013-03-31Updated: 2017-04-20
Phase 2
Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy
CompletedNCT00851786
Start: 2009-04-29End: 2012-01-03Updated: 2021-11-04
Herpes Zoster Vaccine for Bone Marrow Transplant Donors
CompletedNCT01573182
Start: 2012-04-30End: 2018-05-03Updated: 2018-05-11
VZV Vaccine for Hematopoietic Stem Cell Transplantation
CompletedNCT02329457
Start: 2014-12-31End: 2019-10-31Updated: 2019-10-24
Immunogenicity and Safety of Two Lots of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over
CompletedNCT03116594
Start: 2014-01-03End: 2015-03-07Updated: 2017-04-17
Phase 3
Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043)
CompletedNCT00561080
Start: 2007-10-26End: 2009-06-03Updated: 2019-01-11
Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Participants Aged From 50 Years Old (V211-045)
CompletedNCT01391546
Start: 2011-06-20End: 2012-10-15Updated: 2019-01-09
Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over
CompletedNCT03120364
Start: 2015-09-09End: 2016-04-28Updated: 2017-04-19
Phase 4
ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors
NCT02444936
Start: 2015-05-01End: 2018-05-01Updated: 2018-04-06
Safety and Immunogenicity of a Zoster Vaccine in SLE
CompletedNCT02477150
Start: 2015-11-30End: 2019-01-31Updated: 2019-09-04
Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™
CompletedNCT02958345
Start: 2013-06-30End: 2015-07-31Updated: 2017-07-19
Persistence of Protection by Shingrix
CompletedNCT04169009
Start: 2020-07-28End: 2024-06-13Updated: 2024-10-15
Unknown Phase
Zoster Vaccine Response in the Frail Elderly
CompletedNCT01328548
Start: 2011-05-31End: 2015-03-31Updated: 2018-10-29
Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly
CompletedNCT01331161
Start: 2011-07-31End: 2012-10-31Updated: 2016-02-17
Optimal Timing of Zoster Vaccine After Zoster Illness
CompletedNCT02704572
Start: 2016-03-31End: 2017-08-31Updated: 2017-10-13
Optimal Timing of Zoster Vaccine After Hematopoietic Stem Cell Transplantation
CompletedNCT03192319
Start: 2017-07-01End: 2018-08-23Updated: 2019-04-04